2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Status
Withdrawn
2
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
28
Prostatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
9
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Neoplasms
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Neurofibrosarcoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Cholangiocarcinoma
2
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT02947113
2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2
Withdrawn
NCT01936961
2017-06-27
I-CREST
Western Regional Medical Center
Phase NA
Withdrawn